Investment Rating - The report maintains a "Buy-B" rating for the company [1][4]. Core Views - The company has shown significant improvement in its performance for Q3 2025, with revenues reaching 4.381 billion yuan, representing a quarter-on-quarter increase of 6.76% and a year-on-year increase of 13.95%. The net profit attributable to the parent company was 334 million yuan, with a year-on-year increase of 109.13% and a quarter-on-quarter increase of 11.80% [1]. - The growth in revenue is attributed to a reduction in foreign exchange losses and an increase in high-value-added regions and to C business scale [1][2]. - The company is focusing on enhancing its high-value-added product offerings, with the proportion of revenue from North America and Europe increasing to 13.6%, up by 2.7 percentage points year-on-year. The to C business revenue proportion has risen to 41.39%, an increase of 3.66 percentage points year-on-year [2]. - The gross profit margin for Q3 2025 was 23.08%, reflecting a year-on-year increase of 2.52 percentage points and a quarter-on-quarter increase of 0.16 percentage points [2]. - The company is also increasing the proportion of insecticides and fungicides, which now account for 31.70% of its product mix, up by 5.58 percentage points quarter-on-quarter and 4.44 percentage points year-on-year [2]. Financial Data and Valuation - The projected net profits for the company from 2025 to 2027 are 1.14 billion yuan, 1.308 billion yuan, and 1.604 billion yuan, corresponding to price-to-earnings (PE) ratios of 19, 17, and 14 times respectively [4]. - The company’s revenue for 2023 is reported at 11.485 billion yuan, with projections of 13.296 billion yuan for 2024 and 14.122 billion yuan for 2025 [6][14].
润丰股份（301035）：持续向高附加值布局，25Q3业绩同环比改善